3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Polycystic Ovary Syndrome
3
Leukoplakia, Oral
2
Insulin Resistance
2
Diabetes Mellitus
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
1
Sleep Apnea, Obstructive
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Metabolic Syndrome
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Head and Neck Neoplasms
1
Glucose Intolerance
1
Diabetes Mellitus, Type 2
1
Carotid Intimal Medial Thickness 1
1
Carcinoma, Squamous Cell
1
Interventions
Prednisone
112
Docetaxel
87
Leuprolide
79
enzalutamide
72
Abiraterone Acetate
67
bicalutamide
53
Goserelin
50
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
42
Radiotherapy
39
abiraterone
28
Magnetic Resonance Spectroscopy
27
Gonadotropin-Releasing Hormone
24
gallium 68 PSMA-11
23
apalutamide
22
Androgen Antagonists
22
luprolide acetate gel depot
21
sipuleucel-T
20
Radiosurgery
20
Triptorelin Pamoate
18
cabazitaxel
17
cabozantinib
16
Radiotherapy, Intensity-Modulated
16
Flutamide
16
pembrolizumab
15
radium Ra 223 dichloride
14
Prednisolone
14
Nivolumab
14
Dutasteride
14
Dexamethasone
14
Radiation
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Prostatic Neoplasms
×
Pioglitazone
×
Clear all
NCT00427999
2016-11-21
INV342
Novartis
Phase 2
Completed
67 enrolled
6 charts